Gene transfer technologies are essential tools in renal research, allowing precise modulation of gene expression in kidney cells for disease modeling and therapeutic development. Transfection methods, particularly non-viral systems, are widely used due to their ease of use, low immunogenicity, and adaptability to various experimental designs. Advances in lipid-based and nanoparticle-based reagents have enabled effective nucleic acid delivery to kidney cells both in vitro and in vivo, supporting functional studies in nephrology and renal oncology.
In vitro transfection of renal cell lines such as HK-2 and HEK293 facilitates rapid gene silencing and expression studies under controlled conditions. Liposomal reagents tailored for kidney cells, including those developed by Altogen Biosystems, offer high efficiency with minimal cytotoxicity. These formulations are compatible with plasmid DNA, siRNA, and miRNA, supporting applications ranging from transient transfection to stable gene knockdown. Their optimized composition ensures nucleic acid uptake while maintaining cell viability and phenotypic integrity.
In vivo transfection presents greater challenges due to systemic barriers, yet recent developments have enabled efficient renal gene delivery in animal models. The Kidney In Vivo Transfection Kit by Altogen Biosystems uses serum-stable lipid nanoparticles that protect nucleic acids and target renal tissue after intravenous or localized injection. Demonstrated to deliver siRNA and plasmid DNA to both normal kidney tissue and renal tumors, this reagent enables functional studies in disease models with low off-target effects and minimal immune activation.
The choice between in vitro and in vivo approaches depends on the study’s objectives. In vitro systems allow high-throughput screening and mechanistic analysis, while in vivo transfection provides physiological relevance for evaluating gene function and therapeutic effects. Both strategies benefit from transfection reagents optimized for renal applications, with careful consideration of delivery efficiency, tissue specificity, and safety profiles.
Commercial transfection products designed specifically for kidney research have broadened experimental capabilities, enabling gene modulation in both cellular and animal models. The availability of high-performance reagents, such as those offered by Altogen Labs, continues to support advancements in renal biology, drug discovery, and gene therapy research.
Kidney In Vivo Transfection Kit
The Kidney In Vivo Transfection Kit, developed by Altogen Biosystems and supported by in vivo expertise from Altogen Labs, is a specialized non-viral delivery system designed for efficient nucleic acid delivery to renal tissue in live animal models. This reagent enables high-efficiency transfection of siRNA, miRNA, mRNA, and plasmid DNA into mouse and rat kidney tissue, supporting functional genomics, RNA interference studies, and gene expression research.
Formulated with proprietary biodegradable nanoparticle-liposome complexes, the kit allows for systemic or localized (e.g., renal capsule or tumor site) administration, ensuring targeted gene delivery with minimal toxicity. The formulation maintains serum stability and bioavailability post-injection, facilitating consistent in vivo gene knockdown or overexpression in both normal and pathological renal environments.
Validated in multiple rodent models, the Kidney In Vivo Transfection Kit is optimized for use in preclinical studies, including renal disease models, nephrotoxicity assessments, and kidney cancer xenografts. Altogen Labs also offers custom GLP-compliant in vivo transfection services and pharmacology studies utilizing this reagent, supporting comprehensive renal gene function research.
Available in multiple kit sizes to accommodate small-scale pilot studies or large cohort experiments, this product is an essential tool for researchers targeting kidney-specific gene modulation in vivo.
Request Quote here: https://altogen.com/request-quote/
Kidney In Vivo Transfection Kit
VERO Transfection Reagent
The VERO Transfection Reagent, developed by Altogen Biosystems, is a lipid-based transfection formulation specifically designed for high-efficiency delivery of nucleic acids into VERO cells—a continuous line of kidney epithelial cells derived from the African green monkey (Cercopithecus aethiops). These cells are widely used in virology, vaccine production, and toxicology studies due to their stable karyotype and susceptibility to a range of viral infections.
Altogen’s reagent enables efficient transfection of plasmid DNA, siRNA, miRNA, and mRNA while maintaining low cytotoxicity and preserving cellular morphology. Its advanced liposomal structure enhances nucleic acid uptake, facilitates endosomal escape, and promotes strong gene expression or gene silencing outcomes in serum-containing and serum-free conditions.
Validated in both transient and stable transfection protocols, this reagent supports applications including gene function studies, RNA interference, recombinant protein production, and CRISPR/Cas9-mediated genome editing. Its performance has been benchmarked using standard molecular biology assays such as qRT-PCR and western blotting, ensuring reproducibility across experimental replicates.
The VERO Transfection Reagent is manufactured under stringent quality control by Altogen Biosystems and supported by Altogen Labs, a preclinical CRO offering GLP-compliant transfection services, in vivo toxicology studies, and gene expression analyses in VERO and other kidney-derived cell models.
This product is available in multiple sizes to accommodate research scalability, and includes optimized protocols tailored to the unique membrane properties and growth characteristics of VERO cells.
Request Quote here: https://altogen.com/request-quote/
VERO Transfection Reagent (Monkey Kidney Cells)
COS-7 Transfection Reagent
The COS-7 Transfection Reagent from Altogen Biosystems is a specialized lipid-based transfection reagent engineered for high-efficiency delivery of nucleic acids into COS-7 cells (ATCC® CRL-1651™), an SV40-transformed kidney fibroblast-like cell line derived from African green monkey (Cercopithecus aethiops) kidney tissue. COS-7 cells are widely used in molecular biology, virology, and recombinant protein production due to their robust growth, high transfection competency, and ability to support replication of SV40-origin-containing plasmids.
This reagent enables effective transfection of plasmid DNA, siRNA, miRNA, and mRNA, supporting both transient and stable gene expression applications. Formulated to maintain cellular viability and morphology, the COS-7 Transfection Reagent uses proprietary cationic lipid complexes that promote cellular uptake, protect nucleic acids from degradation, and enhance endosomal escape for efficient intracellular delivery.
Validated for use in serum and serum-free conditions, this reagent is ideal for CRISPR-mediated gene editing, reporter gene assays, RNA interference studies, and overexpression of recombinant constructs. Its performance has been confirmed through reproducible gene knockdown and expression results using qRT-PCR, western blotting, and fluorescence imaging.
Manufactured by Altogen Biosystems and backed by Altogen Labs, a full-service preclinical CRO, this product is supported by expert in vitro transfection services, assay development, and custom experimental design. The COS-7 Transfection Reagent is available in multiple volumes to accommodate individual research projects or high-throughput applications.
Request Quote here: https://altogen.com/request-quote/
COS-7 Transfection Reagent (Kidney Cells, CRL-1651)
HEK-293 Transfection Reagent (Epithelial Kidney Cells)
The HEK-293 Transfection Reagent, developed by Altogen Biosystems, is a high-performance lipid-based formulation specifically designed for transfection of HEK-293 cells—an immortalized human embryonic kidney epithelial cell line widely used in gene expression studies, receptor biology, and biotechnology applications. Due to their high proliferative capacity and ease of transfection, HEK-293 cells serve as a foundational model system for evaluating plasmid constructs, protein production, and gene silencing approaches.
This reagent enables efficient intracellular delivery of plasmid DNA, siRNA, miRNA, and mRNA, achieving robust gene expression or knockdown with minimal cytotoxicity. Its proprietary cationic liposome formulation forms stable complexes with nucleic acids, enhances uptake through endocytosis, and facilitates rapid endosomal release—resulting in high transfection efficiency across both serum and serum-free conditions.
Validated in both transient and stable transfection protocols, the HEK-293 Transfection Reagent supports a wide range of downstream applications including CRISPR/Cas9 genome editing, RNA interference studies, reporter gene assays, and recombinant protein expression. Molecular validation by qRT-PCR and western blotting confirms reproducible, high-level transgene delivery across experimental replicates.
Manufactured under strict quality control by Altogen Biosystems and supported by Altogen Labs, a leading GLP-compliant preclinical CRO, this product includes access to expert technical support, optimized protocols, and custom transfection services for HEK-293 cells. The reagent is available in multiple kit sizes, enabling flexibility for both small-scale research and large-scale production environments.
Request Quote here: https://altogen.com/request-quote/
HEK-293 Transfection Reagent (Epithelial Kidney Cells)
MDCK Transfection Reagent (Kidney Cells, CCL-34)
The MDCK Transfection Reagent from Altogen Biosystems is a lipid-based, non-viral transfection reagent optimized for Madin-Darby Canine Kidney (MDCK) cells (ATCC® CCL-34™), a widely used epithelial cell line derived from the kidney of a cocker spaniel. MDCK cells are extensively utilized in studies of epithelial polarity, tight junction biology, influenza virus propagation, and renal transport mechanisms.
This reagent enables efficient transfection of plasmid DNA, siRNA, miRNA, and mRNA with high transgene expression and minimal cytotoxicity. The formulation employs proprietary cationic liposome complexes designed to maximize cellular uptake and intracellular release, while preserving membrane integrity and cell morphology. Transfection efficiency is maintained in both serum-containing and serum-free media, supporting flexibility in experimental design.
Validated for use in transient and stable transfection workflows, the MDCK Transfection Reagent is suitable for a range of applications including gene function studies, epithelial barrier research, CRISPR/Cas9 editing, and viral vector production. Experimental results using this reagent have demonstrated reproducible gene silencing and overexpression validated by qRT-PCR, immunofluorescence, and western blot analysis.
Produced by Altogen Biosystems and supported by Altogen Labs, a GLP-compliant preclinical CRO, this reagent is accompanied by optimized protocols and expert technical support. Altogen Labs offers custom in vitro transfection services and assay development for MDCK cells, enabling full-service solutions in epithelial biology and virology research.
Available in multiple sizes, the MDCK Transfection Reagent is ideal for both small-scale exploratory studies and high-throughput applications in renal and epithelial cell biology.
Request Quote here: https://altogen.com/request-quote/
MDCK Transfection Reagent (Kidney Cells, CCL-34)
Caki-1 Transfection Reagent (Kidney Epithelial Cells)
The Caki-1 Transfection Reagent, developed by Altogen Biosystems, is a proprietary cationic lipid-based formulation specifically engineered for high-efficiency transfection of Caki-1 cells, a human metastatic renal cell carcinoma line derived from kidney epithelial tissue. This cell line is widely used in nephrology, oncology, and molecular signaling studies due to its epithelial morphology and relevance to advanced-stage clear cell renal carcinoma (ccRCC).
The reagent facilitates effective intracellular delivery of plasmid DNA, siRNA, miRNA, and mRNA, achieving robust gene knockdown or overexpression with minimal cytotoxicity. Designed for compatibility with serum-containing and serum-free conditions, it enables high transfection efficiency while maintaining cell viability, morphology, and function—critical for reliable downstream analysis in cancer pathway modulation, drug response studies, and gene function assays.
Validated in both transient and stable transfection protocols, the Caki-1 Transfection Reagent supports a wide array of experimental applications including RNA interference, CRISPR/Cas9-mediated gene editing, oncogene characterization, and tumor suppressor screening. Performance has been confirmed through qRT-PCR, western blotting, and fluorescence imaging for consistent and reproducible results across replicates.
Produced by Altogen Biosystems and supported by Altogen Labs, a GLP-compliant preclinical contract research organization, this reagent is part of a suite of tools offered for renal cancer research. Altogen Labs provides complementary in vitro and in vivo services including transfection optimization, xenograft model studies, and functional genomics analysis using Caki-1 cells.
Available in multiple kit sizes, the Caki‑1 Transfection Reagent delivers a reliable, high-performance solution for kidney cancer research laboratories seeking efficient non-viral gene delivery.
Request Quote here: https://altogen.com/request-quote/
Caki-1 Transfection Reagent (Kidney Epithelial Cells)
293 Transfection Reagent (Emb Kidney, CRL-1573)
The 293 Transfection Reagent, developed by Altogen Biosystems, is a lipid-based transfection formulation designed specifically for HEK 293 cells (ATCC® CRL-1573™), a widely utilized human embryonic kidney cell line. Known for their robust growth and high transfectability, 293 cells are commonly used in molecular biology, virology, and biomanufacturing applications, including recombinant protein expression and viral vector production.
This reagent facilitates the efficient intracellular delivery of plasmid DNA, siRNA, miRNA, and mRNA, enabling both transient and stable gene expression or silencing. Its proprietary cationic liposome complex forms stable nucleic acid-lipid complexes that enhance endocytosis, protect cargo from degradation, and promote effective cytosolic release. The formulation is optimized to preserve cell viability and morphology in both serum-containing and serum-free environments.
Validated for use in high-throughput screening, gene function studies, RNA interference, and CRISPR/Cas9 genome editing, the 293 Transfection Reagent has demonstrated high reproducibility and minimal cytotoxicity. Performance is confirmed through qRT-PCR, western blot, and fluorescent reporter assays, ensuring reliable experimental outcomes across biological replicates.
Manufactured by Altogen Biosystems and supported by Altogen Labs, a GLP-compliant contract research organization specializing in in vitro gene delivery and preclinical assay development, this reagent is accompanied by optimized protocols and expert technical support. Altogen Labs also offers custom transfection services using 293 cells, as well as downstream analytical testing to support gene expression studies and therapeutic development.
Available in multiple volumes, the 293 Transfection Reagent provides a scalable, high-performance solution for laboratories requiring reproducible gene delivery to HEK 293 cells.
Request Quote here: https://altogen.com/request-quote/
293 Transfection Reagent (Emb Kidney, CRL-1573)
BHK-21 Transfection Reagent (Kidney Cells, CCL-10)
The BHK-21 Transfection Reagent, developed by Altogen Biosystems, is a cationic lipid-based transfection reagent formulated for high-efficiency delivery of nucleic acids into BHK-21 cells, a fibroblast-like cell line derived from baby hamster kidney tissue. BHK-21 cells (ATCC® CCL-10™) are widely used in virology, vaccine production, genetic engineering, and recombinant protein expression due to their rapid proliferation and high susceptibility to viral infection.
This reagent enables effective transfection of plasmid DNA, siRNA, miRNA, and mRNA, promoting reliable gene expression and silencing while maintaining low cytotoxicity. Its proprietary liposomal formulation enhances cellular uptake, supports efficient endosomal escape, and maintains high transfection performance in both serum-free and serum-containing conditions.
Validated for both transient and stable transfection workflows, the BHK-21 Transfection Reagent supports a wide range of applications including viral vector development, gene function studies, RNA interference, and CRISPR-based gene editing. Its performance has been confirmed through reproducible results in qRT-PCR, immunofluorescence, and western blot analyses, making it a dependable tool for molecular and cellular biology research.
Manufactured by Altogen Biosystems and supported by Altogen Labs, a leading GLP-compliant preclinical contract research organization, this reagent is backed by expert technical support and optimized transfection protocols. Altogen Labs also provides custom in vitro transfection services, molecular assay development, and gene expression analysis using BHK-21 cells.
Offered in a range of kit sizes to meet the needs of individual research labs and high-throughput facilities, the BHK-21 Transfection Reagent delivers exceptional reliability and transfection efficiency for kidney-derived mammalian cells.
Request Quote here: https://altogen.com/request-quote/